GBI Research
ReportStore
 

 
Browse the latest press releases.
 
 

Media Center

 
 

268 Press Releases

Page 1 of 11
The increased use of targeted therapies, along with a greater uptake of branded drugs and rising incidence population, will cause the breast cancer therapeutics market value to grow from $9.2 billion in 2013 to $13.1 billion by 2020.
Published: 22-Jul-2014
Separator
Europe’s mammography systems market revenue will more than double from approximately $155 million in 2013 to an estimated $423 million by 2020, at a Compound Annual Growth Rate (CAGR) of 15%.
Published: 17-Jul-2014
Separator
A rising diabetes incidence rate will lead the Southeast Asian glucose monitoring devices market value to more than double from $130.4 million in 2013 to $267 million by 2020, at a Compound Annual Growth Rate (CAGR) of 10.8%.
Published: 03-Jul-2014
Separator
The growing market for glucose monitoring devices in Benelux and Scandinavian countries is currently led by Roche, while LifeScan, Bayer and Abbott also hold significant stakes.
Published: 01-Jul-2014
Separator
The global facial aesthetics market will experience rapid growth from $2.5 billion in 2013 to $5.4 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 11%.
Published: 18-Jun-2014
Separator
The Glioblastoma Multiforme (GBM) treatment market is forecast to grow rapidly from $301 million in 2013 to $623 million by 2020, at a Compound Annual Growth Rate (CAGR) of 10.9%.
Published: 11-Jun-2014
Separator
Multiple major drug patent expiries will cause the global anti-hypertensive market value to decline from $40 billion in 2013 to $37.6 billion by 2020, at a negative Compound Annual Growth Rate (CAGR) of 0.9%.
Published: 04-Jun-2014
Separator
The high inflation on the cost of ovarian cancer therapeutics in the US, predominately on Avastin, will drive the global market through to 2020, despite Avastin’s current limitation to off-label usage in the country.
Published: 29-May-2014
Separator
Despite mostly targeting established molecules, the psoriasis pipeline is showing a high level of innovation in first-in-class molecules, including novel angiogenic drugs, growth factors, chaperone proteins and cytokines.
Published: 29-May-2014
Separator
Following the successful development of vaccinations against numerous viral and bacterial diseases, vaccine research and development (R&D) is now targeting areas of high unmet need, and a number of promising strategies are being investigated for novel preventative and therapeutic vaccinations.
Published: 08-May-2014
Separator
Thanks to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics market value will climb from $1.5 billion in 2013 to $2.5 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 7.6%.
Published: 08-May-2014
Separator
Fueled by the increasing global prevalence of pancreatic cancer (PC), coupled with the approval of at least three new drugs, the PC therapeutics market value will climb from $855.8 million in 2012 to approximately $1.21 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 5.1%.
Published: 29-Apr-2014
Separator
Thanks to patent expirations of several key therapies, the Human Immunodeficiency Virus (HIV) treatment market value will increase at a slow pace in the coming years, from $14.3 billion in 2012 to $16.3 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 1.9%.
Published: 15-Apr-2014
Separator
As the prevalence of diabetes continues to expand rapidly across the world, the insulin delivery devices market value is expected to increase from $8.78 billion in 2012 to $13.8 billion by 2019, at a significant Compound Annual Growth Rate (CAGR) of 7%.
Published: 10-Apr-2014
Separator
Despite the elderly being the fastest-growing segment of the global population, only a few of their treatments have been clinically trialed in age-appropriate patients, with many of their therapies still not available in suitable formulations and dosages.
Published: 08-Apr-2014
Separator
The non-small cell lung cancer (NSCLC) therapeutics market value in the Asia-Pacific (APAC) region — Australia, China, India and Japan — is expected to increase moderately over the coming years, climbing from $1.8 billion in 2012 to $2.9 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 6.3%.
Published: 18-Mar-2014
Separator
The epilepsy therapeutics market value in the eight major countries — the US, Canada, France, Germany, Italy, Spain, the UK and Japan — will increase from $3.4 billion in 2012 to $4.5 billion by 2019, at a modest Compound Annual Growth Rate (CAGR) of 3.9%.
Published: 12-Mar-2014
Separator
The global Cystic Fibrosis (CF) market value in the seven major countries (7MM: the US, Canada, France, Germany, Italy, Spain and the UK) will jump from $1.2 billion in 2013 to just under $4.5 billion by 2019, at a massive Compound Annual Growth Rate (CAGR) of 30.4%.
Published: 11-Mar-2014
Separator
The epilepsy therapeutics market value in the Asia-Pacific (APAC) region — Australia, China, India and Japan — is expected to increase moderately, climbing from $1.1 billion in 2012 to $1.5 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 4.7%.
Published: 27-Feb-2014
Separator
While the Systemic Lupus Erythematosus (SLE) treatment market is predominantly limited to Benlysta and off-label Rituxan, new emerging entrants, which appear to offer significant therapeutic benefits, will cause dramatic changes to the future SLE biological treatment market landscape.
Published: 18-Feb-2014
Separator
The systemic psoriasis treatment market value in the eight major countries (8MM) — the US, Canada, France, Germany, Italy, Spain, the UK and Japan — is expected to more than double in the near future, jumping from $5 billion in 2013 to $10.4 billion by 2020, at a significant Compound Annual Growth Rate (CAGR) of 11.1%.
Published: 04-Feb-2014
Separator
Due to a large untreated patient pool and the recent approval of new treatments, the hepatitis C market will more than treble from $5.7 billion in 2012 to $18.6 billion by 2019, at an impressive Compound Annual Growth Rate (CAGR) of 18.5%.
Published: 30-Jan-2014
Separator
The global glucose monitoring devices market value will experience a moderate increase from $9.9 billion in 2012 to $13.7 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 5%.
Published: 28-Jan-2014
Separator
The gastrointestinal (GI) therapeutics market for Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD) in the Asia-Pacific (APAC) region will increase in value from $564m in 2012 to $784m by 2019, at a Compound Annual Growth Rate (CAGR) of 4.8%.
Published: 28-Jan-2014
Separator
The global market for traditional wound management will climb from $1.6 billion in 2012 to $1.9 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 2.1%, as the therapy continues to be the primary mode of treatment in developing countries.
Published: 22-Jan-2014